文献速递临床试验与 GCP流行病学与生物统计

抗菌治疗对特发性肺纤维化成人呼吸住院或死亡的影响:CleanUP-IPF随机临床试验

Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

这项在美国35个中心开展的实效性随机非盲试验纳入513例40岁以上特发性肺纤维化患者,比较常规治疗联合抗菌药物(复方磺胺甲噁唑或多西环素)与单用常规治疗。因无效于2019年12月18日终止。

要点

  • 抗菌治疗未改善特发性肺纤维化患者的呼吸住院或死亡风险。
  • 抗菌组腹泻和皮疹等不良事件发生率高于单用常规治疗组。

核心结论

  • 在特发性肺纤维化成人中,常规治疗联合复方磺胺甲噁唑或多西环素与单用常规治疗相比,未显著改善非择期呼吸住院或死亡时间。
  • 这些发现不支持使用这些抗生素治疗基础疾病。

研究设计与样本

  • 实效性、随机、非盲临床试验,在美国35个中心开展。
  • 2017年8月至2019年6月随机513例40岁以上患者,最终随访至2020年1月。
  • 按1:1分配至抗菌药物组(n=254)或单用常规治疗组(n=259)。

主要发现

  • 平均随访13.1个月(中位12.7个月),共发生108例主要终点事件。
  • 抗菌组52例事件(20.4/100患者年,95%CI 14.8-25.9),常规治疗组56例(18.4/100患者年,95%CI 13.2-23.6)。

关键数值与推荐

  • 主要终点:首次非择期呼吸住院或全因死亡时间。
  • 复方磺胺甲噁唑用法:甲氧苄啶160mg/磺胺甲噁唑800mg每日两次,加叶酸5mg每日一次(n=128)。
  • 多西环素用法:体重<50kg者100mg每日一次,≥50kg者100mg每日两次(n=126)。

临床怎么用

  • 不应将复方磺胺甲噁唑或多西环素用于特发性肺纤维化的基础疾病治疗。
  • 临床决策应基于常规治疗,抗菌药物仅按其他适应证使用。

局限性

  • 试验为非盲设计,常规治疗组未使用安慰剂。
  • 研究因无效提前终止。
  • 平均随访13.1个月,长期效应未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Alteration in lung microbes is associated with disease progression in idiopathic pulmonary fibrosis. OBJECTIVE: To assess the effect of antimicrobial therapy on clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: Pragmatic, randomized, unblinded clinical trial conducted across 35 US sites. A total of 513 patients older than 40 years were randomized from August 2017 to June 2019 (final follow-up was January 2020). INTERVENTIONS: Patients were randomized in a 1:1 allocation ratio to receive antimicrobials (n = 254) or usual care alone (n = 259). Antimicrobials included co-trimoxazole (trimethoprim 160 mg/sulfamethoxazole 800 mg twice daily plus folic acid 5 mg daily, n = 128) or doxycycline (100 mg once daily if body weight <50 kg or 100 mg twice daily if ≥50 kg, n = 126). No placebo was administered in the usual care alone group. MAIN OUTCOMES AND MEASURES: The primary end point was time to first nonelective respiratory hospitalization or all-cause mortality. RESULTS: Among the 513 patients who were randomized (mean age, 71 years; 23.6% women), all (100%) were included in the analysis. The study was terminated for futility on December 18, 2019. After a mean follow-up time of 13.1 months (median, 12.7 months), a total of 108 primary end point events occurred: 52 events (20.4 events per 100 patient-years [95% CI, 14.8-25.9]) in the usual care plus antimicrobial therapy group and 56 events (18.4 events per 100 patient-years [95% CI, 13.2-23.6]) in the usual care group, with no significant difference between groups (adjusted HR, 1.04 [95% CI, 0.71-1.53; P = .83]. There was no statistically significant interaction between the effect of the prespecified antimicrobial agent (co-trimoxazole vs doxycycline) on the primary end point (adjusted HR, 1.15 [95% CI 0.68-1.95] in the co-trimoxazole group vs 0.82 [95% CI, 0.46-1.47] in the doxycycline group; P = .66). Serious adverse events occurring at 5% or greater among those treated with usual care plus antimicrobials vs usual care alone included respiratory events (16.5% vs 10.0%) and infections (2.8% vs 6.6%); adverse events of special interest included diarrhea (10.2% vs 3.1%) and rash (6.7% vs 0%). CONCLUSIONS AND RELEVANCE: Among adults with idiopathic pulmonary fibrosis, the addition of co-trimoxazole or doxycycline to usual care, compared with usual care alone, did not significantly improve time to nonelective respiratory hospitalization or death. These findings do not support treatment with these antibiotics for the underlying disease. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02759120.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Martinez FJ, Yow E, Flaherty KR, et al. Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial. JAMA. 2021. PMID: 33974018. doi:10.1001/jama.2021.4956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。